EicOsis

Executive Summary

EicOsis is a clinical-stage biotech company developing novel, non-addictive oral therapeutics for chronic pain and inflammation. Its unique approach targets the soluble Epoxide Hydrolase (sEH) enzyme, which boosts the body's natural anti-inflammatory and pain-relieving compounds. The lead candidate is currently in Phase 1 trials, aiming to provide a safer alternative to opioids and address the ongoing opioid crisis. Founded in 2015 and headquartered in Davis, California, EicOsis is privately held and has not yet disclosed its total funding or valuation. The company's focus on a first-in-class mechanism for pain management positions it as a potential game-changer in the chronic pain space, offering an innovative solution that could reduce reliance on addictive medications. EicOsis's progress in Phase 1 is a critical milestone, and upcoming data readouts will be key to validating its therapeutic platform. The company's strategy involves leveraging the body's endogenous pathways to manage pain without the risks of addiction or tolerance. As a private company, EicOsis may seek additional financing or partnerships to advance its pipeline. With a strong scientific rationale and a clear unmet need, EicOsis is well-positioned to attract interest from investors and pharmaceutical partners. However, as with all early-stage biotechs, clinical and regulatory risks remain, and successful navigation of Phase 1 will be essential for future development.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 top-line data readout70% success
• Q4 2026Initiation of Phase 2 trial planning60% success
• H2 2026Partnership or licensing deal for sEH platform40% success